Quality Improvement Case Study: Warfarin Sodium Interactions

Journal of the American Medical Directors Association

Volumn 7, Issue 5, 2006, Pages 315-318

  Weinberg, Andrew D ^a,b   Altman, Julie S ^c   Pals, Jean K ^b,d  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WJB Dorn VA Medical Center   (United States)

^c University of South Carolina   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBIDOPA PLUS LEVODOPA; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; FUROSEMIDE; GLIBENCLAMIDE; METRONIDAZOLE; PARACETAMOL; PENICILLIN DERIVATIVE; PROTHROMBIN; RIFAMPICIN; RIFAMYCIN; TETANUS TOXOID; VITAMIN K GROUP; WARFARIN;

AGED; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONFIDENTIALITY; DEATH CERTIFICATE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENTIATION; FALLING; FEMALE; HEAD INJURY; HEALTH CARE FACILITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LAW SUIT; LIVER METABOLISM; NURSING CARE; PAIN; PARKINSON DISEASE; QUALITY CONTROL; URINARY TRACT INFECTION;

EID: 33744803469     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.04.004     Document Type: Article

References (13)

1. Petersen P., Boysen G., Godtfredsen J., et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1 (1989) 175-179
2. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323 (1990) 1505-1511
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study. Final results. Circulation 84 (1991) 527-539
4. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 327 (1992) 1406-1412
5. Connolly S.J., Laupacis A., Gent M., et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 18 (1991) 349-355
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
7. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 (1993) 1255-1262
8. Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. A meta-analysis. Ann Intern Med 131 (1999) 492-501
9. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 429S-456S
10. Hylek E.M., and Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120 (1994) 897-902
11. Cannegieter S.C., Rosendaal F.R., Wintzen A.R., et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333 (1995) 11-17
12. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
13. Thomson Micromedex, Greenwood Village, CO. Available at: www.thomsonmicromedex.com. 2005.